相似文献
1
The Use of N-Terminal-Pro-BNP in Preterm Infants.
Int J Pediatr. 2009;2009:175216. doi: 10.1155/2009/175216. Epub 2009 Dec 30.
2
B-type and N-terminal pro-B-type natriuretic peptides are equally useful in assessing patent ductus arteriosus in very preterm infants.
Acta Paediatr. 2015 Apr;104(4):e139-42. doi: 10.1111/apa.12892. Epub 2015 Feb 4.
3
Biochemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death or severe intraventricular haemorrhage.
Arch Dis Child Fetal Neonatal Ed. 2008 Nov;93(6):F407-12. doi: 10.1136/adc.2007.133140. Epub 2008 Feb 19.
4
Troponin T, N-terminal pro natriuretic peptide and a patent ductus arteriosus scoring system predict death before discharge or neurodevelopmental outcome at 2 years in preterm infants.
Arch Dis Child Fetal Neonatal Ed. 2011 Mar;96(2):F133-7. doi: 10.1136/adc.2010.185967. Epub 2010 Nov 11.
5
Cardiac troponin T and N-terminal-pro-B type natriuretic peptide reflect myocardial function in preterm infants.
J Perinatol. 2008 Jul;28(7):482-6. doi: 10.1038/jp.2008.21. Epub 2008 Mar 6.
6
Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants.
Pediatrics. 2005 Mar;115(3):e255-61. doi: 10.1542/peds.2004-1837. Epub 2005 Feb 1.
7
B-type natriuretic peptide levels normalise in preterm infants without a patent ductus arteriosus by the fifth postnatal day.
Acta Paediatr. 2016 Aug;105(8):e352-5. doi: 10.1111/apa.13480. Epub 2016 Jun 10.
8
Cardiac biomarkers and haemodynamically significant patent ductus arteriosus in preterm infants.
Early Hum Dev. 2017 Feb;105:41-47. doi: 10.1016/j.earlhumdev.2016.12.007. Epub 2016 Dec 18.
9
Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants.
Acta Paediatr. 2001 Feb;90(2):184-91. doi: 10.1080/080352501300049406.
10
Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants.
Clin Sci (Lond). 2002 Jul;103(1):75-7. doi: 10.1042/cs1030075.
引用本文的文献
1
NT-proBNP, to be or not to be a BPD biomarker?
Pediatr Res. 2024 Oct 31. doi: 10.1038/s41390-024-03681-8.
2
Should we "eliminate" PDA shunt in preterm infants? A narrative review.
Front Pediatr. 2024 Feb 6;12:1257694. doi: 10.3389/fped.2024.1257694. eCollection 2024.
3
Brain natriuretic peptide and N-terminal brain natriuretic peptide for the diagnosis of haemodynamically significant patent ductus arteriosus in preterm neonates.
Cochrane Database Syst Rev. 2022 Dec 8;12(12):CD013129. doi: 10.1002/14651858.CD013129.pub2.
4
Can NT-proBNP Levels Be an Early Biomarker of Reduced Left Ventricular Ejection Fraction in Preterm Infants?
Children (Basel). 2022 Jul 3;9(7):1002. doi: 10.3390/children9071002.
5
Patent ductus arteriosus in preterm infants: is early transcatheter closure a paradigm shift?
J Perinatol. 2019 Nov;39(11):1449-1461. doi: 10.1038/s41372-019-0506-7. Epub 2019 Sep 27.
6
Early prediction of spontaneous Patent Ductus Arteriosus (PDA) closure and PDA-associated outcomes: a prospective cohort investigation.
BMC Pediatr. 2019 Sep 13;19(1):333. doi: 10.1186/s12887-019-1708-z.
本文引用的文献
1
Early N-terminal pro-brain natriuretic peptide measurements predict clinically significant ductus arteriosus in preterm infants.
Acta Paediatr. 2009 Aug;98(8):1254-9. doi: 10.1111/j.1651-2227.2009.01315.x. Epub 2009 Apr 30.
2
N-terminal probrain natriuretic peptide and patent ductus arteriosus in preterm infants.
J Perinatol. 2009 Feb;29(2):137-42. doi: 10.1038/jp.2008.185. Epub 2008 Nov 20.
3
NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies.
Pediatr Cardiol. 2009 Jan;30(1):3-8. doi: 10.1007/s00246-008-9258-4. Epub 2008 Jul 4.
4
Risk stratification in neonates and infants submitted to cardiac surgery with cardiopulmonary bypass: a multimarker approach combining inflammatory mediators, N-terminal pro-B-type natriuretic peptide and troponin I.
Cytokine. 2008 Jun;42(3):317-24. doi: 10.1016/j.cyto.2008.03.005. Epub 2008 Apr 15.
5
Cardiac troponin T and N-terminal-pro-B type natriuretic peptide reflect myocardial function in preterm infants.
J Perinatol. 2008 Jul;28(7):482-6. doi: 10.1038/jp.2008.21. Epub 2008 Mar 6.
6
Biochemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death or severe intraventricular haemorrhage.
Arch Dis Child Fetal Neonatal Ed. 2008 Nov;93(6):F407-12. doi: 10.1136/adc.2007.133140. Epub 2008 Feb 19.
7
N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus.
Arch Dis Child Fetal Neonatal Ed. 2008 Jul;93(4):F257-60. doi: 10.1136/adc.2007.120691. Epub 2008 Jan 24.
8
Quantitative assessment of the degree of ductal steal using celiac artery blood flow to left ventricular output ratio in preterm infants.
Neonatology. 2008;93(3):206-12. doi: 10.1159/000110869. Epub 2007 Nov 9.
9
Towards rational management of the patent ductus arteriosus: the need for disease staging.
Arch Dis Child Fetal Neonatal Ed. 2007 Nov;92(6):F424-7. doi: 10.1136/adc.2007.118117.
10
N-terminal pro-B-type natriuretic peptide as a marker of ductal haemodynamic significance in preterm infants: a prospective observational study.
Arch Dis Child Fetal Neonatal Ed. 2007 Sep;92(5):F421-2. doi: 10.1136/adc.2007.119701.
Zotero 插件